Home > Resources > Whitepapers > CELL THERAPY: FROM RESEARCH TO COMMERCIALIZATION

CELL THERAPY: FROM RESEARCH TO COMMERCIALIZATION

March 5, 2019

In cell therapy, cells are introduced into the human body to either replace endogenous dead/non-functioning cells or to modulate dysfunctional cellular mechanisms. While cell therapy has been closely linked historically to regenerative medicine, the therapeutic potential of nonprogenitor cell therapy has been extensively investigated more recently, particularly the anti-cancer potential of immune cell transfer.

Spotlight

Sutro Biopharma, Inc.

Sutro Biopharma is a biopharmaceutical company that develops and designs novel protein therapeutics and biosuperiors that have site-directed modifications, including modifications incorporating non-natural amino acids. Sutro's biochemical protein synthesis technology opens up opportunities to create protein therapeutics that cannot be produced using conventional methods. Sutro’s technology enables the rapid and systematic exploration of many protein drug variants to identify drug candidates. Once identified, the company can efficiently scale production to commercial levels.

OTHER WHITEPAPERS

Gene, Cell, & RNA Therapy Landscape

whitePaper | January 24, 2022

The American Society of Gene & Cell Therapy (ASGCT) is the primary professional membership organization.

Producing therapeutic peptides using biotechnology

whitePaper | October 20, 2022

We began the project by working to the design of a recombinant bacterial strain selection of a strain capable of producing high concentrations of peptides.

A REVIEW OF THE RESEARCH TRENDS AND DEVELOPMENTS

whitePaper | May 9, 2022

In the last decade, there has been an encouraging shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine.

BIOTECHNOLOGY INNOVATION ORGANIZATION

whitePaper | January 4, 2022

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to participate in the 2022 Special 301 Review: Identification of Countries under Section 182 of the Trade Act of 1974: Request for Public Comment and Announcement of Public Hearing.

2022 Biosimilars Report: The U.S. Journey and Path Ahead

whitePaper | June 8, 2022

Cardinal Health is fortunate to sit at the crossroads of the United States (U.S.) healthcare system, engaging with stakeholders from across the industry including healthcare

Long-term follow-up studies of cell and gene therapies

whitePaper | September 29, 2022

The market is experiencing a surge in the availability of cell and gene therapies (CGTs); it’s estimated that by 2025 as many as 20 will be introduced into the US each year.1,2